APOBEC3D and APOBEC3F Potently Promote HIV-1 Diversification and Evolution in Humanized Mouse Model

Several APOBEC3 proteins, particularly APOBEC3D, APOBEC3F, and APOBEC3G, induce G-to-A hypermutations in HIV-1 genome, and abrogate viral replication in experimental systems, but their relative contributions to controlling viral replication and viral genetic variation in vivo have not been elucidated. On the other hand, an HIV-1-encoded protein, Vif, can degrade these APOBEC3 proteins via a ubiquitin/proteasome pathway. Although APOBEC3 proteins have been widely considered as potent restriction factors against HIV-1, it remains unclear which endogenous APOBEC3 protein(s) affect HIV-1 propagation in vivo. Here we use a humanized mouse model and HIV-1 with mutations in Vif motifs that are responsible for specific APOBEC3 interactions, DRMR/AAAA (4A) or YRHHY/AAAAA (5A), and demonstrate that endogenous APOBEC3D/F and APOBEC3G exert strong anti-HIV-1 activity in vivo. We also show that the growth kinetics of 4A HIV-1 negatively correlated with the expression level of APOBEC3F. Moreover, single genome sequencing analyses of viral RNA in plasma of infected mice reveal that 4A HIV-1 is specifically and significantly diversified. Furthermore, a mutated virus that is capable of using both CCR5 and CXCR4 as entry coreceptor is specifically detected in 4A HIV-1-infected mice. Taken together, our results demonstrate that APOBEC3D/F and APOBEC3G fundamentally work as restriction factors against HIV-1 in vivo, but at the same time, that APOBEC3D and APOBEC3F are capable of promoting viral diversification and evolution in vivo.

[1]  R. König,et al.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome , 2004, Nature Structural &Molecular Biology.

[2]  O. Schwartz,et al.  The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells , 2010, The Journal of experimental medicine.

[3]  C. Cheng‐Mayer,et al.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[5]  Thomas Lengauer,et al.  Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.

[6]  M. Davenport,et al.  APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome , 2012, Retrovirology.

[7]  M. Malim,et al.  APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts , 2008, PLoS pathogens.

[8]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[9]  M. Emerman,et al.  Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.

[10]  Mamoru Ito,et al.  A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. , 2011, Blood.

[11]  V. Pathak,et al.  Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif , 2008, Journal of Virology.

[12]  M. Stenglein,et al.  APOBEC3 proteins mediate the clearance of foreign DNA from human cells , 2010, Nature Structural &Molecular Biology.

[13]  S. Pillai,et al.  Turning up the volume on mutational pressure: Is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3) , 2008, Retrovirology.

[14]  J. Garcia,et al.  HIV Restriction by APOBEC3 in Humanized Mice , 2013, PLoS pathogens.

[15]  A. Meyerhans,et al.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes , 1991, Journal of virology.

[16]  Mamoru Ito,et al.  Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. , 2009, Virology.

[17]  M. Malim,et al.  Suppression of HIV-1 Infection by APOBEC3 Proteins in Primary Human CD4+ T Cells Is Associated with Inhibition of Processive Reverse Transcription as Well as Excessive Cytidine Deamination , 2012, Journal of Virology.

[18]  J. Fellay,et al.  Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.

[19]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[20]  Lela Lackey,et al.  Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1 , 2011, Journal of Virology.

[21]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[22]  R. Harris,et al.  Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n , 2012, PLoS pathogens.

[23]  J. Fitzgibbon,et al.  A new type of G-->A hypermutation affecting human immunodeficiency virus. , 1993, AIDS research and human retroviruses.

[24]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[25]  W. Brown,et al.  APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.

[26]  N. A. Temiz,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[27]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[28]  Mamoru Ito,et al.  Vpu Augments the Initial Burst Phase of HIV-1 Propagation and Downregulates BST2 and CD4 in Humanized Mice , 2012, Journal of Virology.

[29]  N. Kadowaki,et al.  APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells , 2012, Scientific Reports.

[30]  Ramón Doallo,et al.  CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics , 2012, Nature Methods.

[31]  C. Burant,et al.  Molecular cloning of an apolipoprotein B messenger RNA editing protein. , 1993, Science.

[32]  F. McCutchan,et al.  Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.

[33]  A. Criscuolo morePhyML: improving the phylogenetic tree space exploration with PhyML 3. , 2011, Molecular phylogenetics and evolution.

[34]  M. Khan,et al.  Stably Expressed APOBEC3F Has Negligible Antiviral Activity , 2010, Journal of Virology.

[35]  M. Neuberger,et al.  DNA deamination in immunity: AID in the context of its APOBEC relatives. , 2007, Advances in immunology.

[36]  W. Sugiura,et al.  Use of New T-Cell-Based Cell Lines Expressing Two Luciferase Reporters for Accurately Evaluating Susceptibility to Anti-Human Immunodeficiency Virus Type 1 Drugs , 2006, Journal of Clinical Microbiology.

[37]  Michel Henry,et al.  Sustained G-->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. , 2002, The Journal of general virology.

[38]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[39]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[40]  Mamoru Ito,et al.  Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. , 2010, Vaccine.

[41]  Kaoru Tominaga,et al.  Activation of innate immune antiviral response by NOD2 , 2009, Nature Immunology.

[42]  B. Blom,et al.  Use of a Novel Chimeric Mouse Model with a Functionally Active Human Immune System To Study Human Immunodeficiency Virus Type 1 Infection , 2007, Clinical and Vaccine Immunology.

[43]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[44]  Y. Koyanagi,et al.  The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models , 2011, Experimental biology and medicine.

[45]  S. Wain-Hobson,et al.  Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication , 2006, Nucleic acids research.

[46]  Bette Korber,et al.  HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC , 2009, PLoS pathogens.

[47]  M. Nei,et al.  Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.

[48]  A. Takaori-Kondo,et al.  Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. , 2008, Mini reviews in medicinal chemistry.

[49]  Kazuyuki Aihara,et al.  HIV-1 Vpr Accelerates Viral Replication during Acute Infection by Exploitation of Proliferating CD4+ T Cells In Vivo , 2013, PLoS pathogens.

[50]  Robert F. Siliciano,et al.  Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors , 2007, Journal of Virology.

[51]  R. McClelland,et al.  Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif , 2009, Journal of Virology.

[52]  K. Aihara,et al.  Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation , 2014, Journal of Virology.

[53]  Yi Zang,et al.  Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif , 2014, Nature.

[54]  Jianzhi Zhang Evolution by gene duplication: an update , 2003 .

[55]  W. J. Esselman,et al.  Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family , 2006, Journal of Virology.

[56]  S. Mboup,et al.  The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. , 2008, AIDS research and human retroviruses.

[57]  Nelson L Michael,et al.  Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. , 2008, Virology.

[58]  Yuetsu Tanaka,et al.  Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins , 2007, Journal of Virology.

[59]  M. Malim,et al.  Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination , 2006, Journal of Virology.

[60]  V. Pathak,et al.  Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F , 2007, Journal of Virology.

[61]  Huldrych F Günthard,et al.  2011 update of the drug resistance mutations in HIV-1. , 2011, Topics in antiviral medicine.

[62]  W. Brown,et al.  Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. , 2014, Virology.

[63]  M. Malim,et al.  Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets , 2009, Journal of Virology.

[64]  Mamoru Ito,et al.  Remarkable Lethal G-to-A Mutations in vif-Proficient HIV-1 Provirus by Individual APOBEC3 Proteins in Humanized Mice , 2010, Journal of Virology.

[65]  W. Greene,et al.  Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells* , 2006, Journal of Biological Chemistry.

[66]  W. Brown,et al.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction , 2010, Nucleic acids research.

[67]  V. Pathak,et al.  Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance , 2009, PLoS pathogens.

[68]  V. Pathak,et al.  APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE in Human Primary CD4+ T Cells and Macrophages , 2012, Journal of Virology.

[69]  M. Si-Tahar,et al.  Innate Sensing of HIV-Infected Cells , 2011, PLoS pathogens.

[70]  Ariana Harari,et al.  Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes , 2010, Journal of Virology.

[71]  D. Ho,et al.  Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.

[72]  V. Pathak,et al.  Identification of Specific Determinants of Human APOBEC3F, APOBEC3C, and APOBEC3DE and African Green Monkey APOBEC3F That Interact with HIV-1 Vif , 2010, Journal of Virology.

[73]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[74]  J. Hoxie,et al.  Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions , 1999, Journal of Virology.

[75]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[76]  M. Kawahara,et al.  HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication , 2010, Proceedings of the National Academy of Sciences.

[77]  V. Pathak,et al.  APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms , 2010, Journal of Virology.

[78]  S. Conticello The AID/APOBEC family of nucleic acid mutators , 2008, Genome Biology.

[79]  O. Strannegard,et al.  Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. , 1991, AIDS research and human retroviruses.

[80]  M. Malim,et al.  APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation , 2007, Journal of Biological Chemistry.